FENC - Fennec Pharmaceuticals

-

$undefined

N/A

(N/A)

Fennec Pharmaceuticals NASDAQ:FENC Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation in the U.S. for this potential use. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans.

Location: PO Box 13628, 68 Tw Alexander Dr, North Carolina, 27709-3628, US | Website: fennecpharma.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

137.6M

Cash

26.63M

Avg Qtr Burn

N/A

Short % of Float

9.99%

Insider Ownership

16.18%

Institutional Own.

58.47%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.